Comments
Natco Pharma Ltd’s consolidated net profit declined 35 per cent at Rs 118 crore in the second quarter ended September 30, 2019 compared to Rs 182 crore in the corresponding quarter of previous year.
The total revenue of the Hyderabad-based company also declined 11 per cent at Rs 519 crore as against Rs 583 crore in the year-ago period.
``The decline in revenues and profits compared to the same period last year is primarily due to the anticipated drop in oseltamivir product sales in the USA and Hep C sales in India,’’ Natco said in a release on Tuesday.
The board of directors has recommended second interim dividend of Rs 1.00 per equity share of Rs 2.00 each.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.